11.26.2014  |   | Subscribe  | Contact us

All News & Blogs

E-mail Alerts

Local doctor is part of study
Patients can participate in national cancer trials in the Fredericksburg office of Dr. Frederick Tucker

 Dr. Frederick Tucker is now offering clinical trials sanctioned by the National Cancer Institute.
Visit the Photo Place
Date published: 1/7/2008


As part of their chemotherapy treatments, many colon cancer patients receive a cocktail of three drugs: leucovorin, oxaliplatin and 5-FU.

But what if a fourth drug, bevacizumab, was added to the mix?

Bevacizumab stops tumor growth by preventing the formation of new blood vessels. Would it help colon cancer patients?

That question is being asked and answered now in hospitals and doctors' offices across the country, including one in Fredericksburg. Dr. Frederick C. Tucker Jr. has joined a National Cancer Institute study that adds bevacizumab to the traditional regimen for colon cancer patients.

The study is part of a program that moves clinical studies from large academic centers into smaller community settings. Tucker, an oncologist, is hosting 22 NCI-sponsored clinical trials. He is one of more than 3,300 doctors nationwide taking part in the federal agency's Community-Clinical Oncology Program.

Tucker joined the 24-year-old program in May, believing that local patients want to participate in major cancer trials and prefer to stay close to home to do it.

"Now patients don't have to travel to Baltimore or Charlottesville to get access to those trials," Tucker said.

So far about 15 patients have enrolled in the trials. Delores Arrington was one of them.

Arrington, a 45-year-old resident of Fredericksburg, was diagnosed with breast cancer in June and had a double mastectomy at Mary Washington Hospital in July.

From September through November she received chemotherapy in Tucker's office as a subject in one of the NCI studies. She will begin radiation treatments soon.

Arrington's chemo trial is called CALGB-4101. It divides women with breast cancer into two groups. Both groups receive cyclophosphamide and doxorubicin. One of the groups also receives a third drug, paclitaxel.

"That's very typical of these trials: the standard and the standard plus some modification." Tucker said.

The women receive the drugs for up to three months and are checked regularly to see how they do.

Arrington was a nursing assistant at Mary Washington Hospital until she was diagnosed with cancer.

She said she participated in the clinical trial in hopes of receiving state-of-the-art treatment, but also to advance medical knowledge.

"We have daughters, and we have sons," she said. "I have brothers and sisters and so does my husband. Working in the medical field, why wouldn't you want to help the future."

1  2  Next Page  

Physicians such as Dr. Frederick Tucker are doing clinical trials in their private offices. But much of the medical research in the Fredericksburg area is taking place at Mary Washington Hospital.

At present, 16 clinical trials and research studies are under way at the hospital.

The following includes the physicians, nurses and social workers doing hospital- approved studies and the purpose of these studies.

Dr. Daniel Hoffman:

Study to see if public screenings will detect prostate cancer early.

Dr. Robert Vranian:

Study of the wireless transmission of electrocardiograms from a hand-held device.

Dr. Robert Vranian:

Studies of an anticoagulant drug and a heart drug.

Dr. Thomas Martyak:

Study of the Jostent coronary stent.

Donna Driver:

Study of a treatment for heel ulcers.

Dr. Jeffrey Rehm:

Studies of drugs used to treat pulmonary embolism.

Yvonne Jackson:

Study of a bowel preparation protocol.

Dr. Henry Clemo:

Studies of remote monitoring of patients with heart failure.

Dr. Frans Vossenberg:

Study of a heart drug.

Chien-yun Wu:

Study of the link between coping style and depression in patients with chronic illness.

Dr. Victor D'Addio:

Study of a drug used for peripheral arterial disease.

Dr. Jeffrey Askew:

Study of a drug used to prevent stroke and embolisms.

Dr. Norman Bernstein:

Study of an HIV drug.

Dr. Maha Alattar:

Study of a sleep drug for stroke patients.

Dr. Timothy Sherwood:

Study of non-small-cell lung cancer.

--Jim Hall